GlassScriptPhysician profile
Micah Matthew Burch
NPI 1932367893
$220,813.47
in general payments reported to CMS, 2019-2025
56 companies · $41K in 2025
The $41K reported for 2025 was more than what 94% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $12K · 2021: $24K · 2022: $45K · 2023: $56K · 2024: $20K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Travel and Lodging: $13K · Food and Beverage: $7,868 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,491.25 |
| Travel and Lodging | $12,895.87 |
| Food and Beverage | $7,868.41 |
| Education | $281.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $143,898.72 | 2019-2025 | Carvykti, Rybrevant, Tecvayli |
| Pharmacyclics LLC, An Abbvie Company | $48,719.60 | 2019-2023 | Imbruvica, Epkinly |
| Janssen Pharmaceuticals, INC | $14,117.97 | 2019 | |
| Genentech USA, INC. | $5,307.61 | 2019-2023 | Lunsumio, Polivy |
| Seagen INC. | $1,568.87 | 2021-2023 | Adcetris |
| Incyte Corporation | $722.51 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $617.26 | 2019-2025 | |
| Abbvie INC. | $416.32 | 2019-2025 | Venclexta |
| Rigel Pharmaceuticals, INC. | $372.50 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $323.79 | 2020-2025 | Lynparza, Enhertu, Calquence |
| Kite Pharma, INC. | $305.30 | 2021-2025 | Yescarta |
| Amgen INC. | $284.47 | 2019-2021 | |
| Adc Therapeutics America, INC. | $278.43 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $263.46 | 2021-2025 | |
| Beigene USA, INC. | $240.58 | 2020-2025 | Brukinsa |
Show all 54 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micah Burch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.